Eva Serasli
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Eva Serasli has a total of 21 co-authors. Here are the top co-authors by number of shared publications:
- Venetia Tsara
12nd Chest Department, General Hospital "G. Papanikolaou," (Exohi), Thessaloniki, GR-57010, Greece
2 shared publications Andreas Kosmas
1 shared publication- Angelos Megalopoulos
Cardiovascular Department, General Hospital G. Papanikolaou, Thessaloniki, Greece
1 shared publication D Siopi
1 shared publication- George Trellopoulos
Vascular Surgery Department, “G. Papanikolaou” Hospital, 57010 Thessaloniki, Greece
1 shared publication - Georgia Papaioannou
Hematology Department, Papageorgiou General Hospital, Thessaloniki, Greece
1 shared publication
Latest Publications
- Open Access
- 26 April 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 163
Low-pressure pulmonary artery aneurysm presenting with pulmonary embolism: a case series
Pulmonary artery aneurysm is an uncommon disorder with severe complications. The diagnosis is often difficult, since the clinical manifestations are non-specific and the treatment is controversial, as the natural history of the disease is not completely understood.
- 26 April 2011
- Published by Springer Nature in Journal of Medical Case Reports
- Vol. 5 (1) , 163
Open AccessLow-pressure pulmonary artery aneurysm presenting with pulmonary embolism: a case series
Pulmonary artery aneurysm is an uncommon disorder with severe complications. The diagnosis is often difficult, since the clinical manifestations are non-specific and the treatment is controversial, as the natural history of the disease is not completely understood.
- 1 November 2010
- Published by Bentham Science Publishers Ltd. in Recent Patents on Cardiovascular Drug Discovery
- Vol. 5 (3) , 184-195
Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which has been proved to be effective in the treatment of pulmonary arterial hypertension (PAH). This review critically addresses and highlights pharmacological aspects of bosentan such as safety, tolerability and drug interactions. The biological basis of its mode of action is demonstrated in preclinical studies on animal models of PH and an up-to-date review of clinical data is provided, supporting its practical use with a view to achieve optimal treatment goals. Major pivotal randomized placebo-control clinical trials are discussed, together with recently published data concerning its promising role as part of combination therapy. Furthermore, recent patents of novel pharmaceutical interventions in the field of PAH, expanding treatment options, are presented.
- 1 November 2010
- Published by Bentham Science Publishers Ltd. in Recent Patents on Cardiovascular Drug Discovery
- Vol. 5 (3) , 184-195
Review on Bosentan, A Dual Endothelin Receptor Antagonist for the Treatment of Pulmonary Arterial Hypertension
The dual endothelin receptor antagonist, bosentan, is an orally active therapy, which has been proved to be effective in the treatment of pulmonary arterial hypertension (PAH). This review critically addresses and highlights pharmacological aspects of bosentan such as safety, tolerability and drug interactions. The biological basis of its mode of action is demonstrated in preclinical studies on animal models of PH and an up-to-date review of clinical data is provided, supporting its practical use with a view to achieve optimal treatment goals. Major pivotal randomized placebo-control clinical trials are discussed, together with recently published data concerning its promising role as part of combination therapy. Furthermore, recent patents of novel pharmaceutical interventions in the field of PAH, expanding treatment options, are presented.
- 1 August 2008
- Vol. 27 (4) , 319-28
Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes.
Bronchial artery embolization (BAE) is a well-established, non-surgical procedure in the emergency treatment of massive hemoptysis. This study aims to evaluate the immediate and long-term prognosis of BAE for the management of massive hemoptysis in our center. Twenty consecutive patients (mean age: 59+/-14 years) with massive hemoptysis, underwent BAE with microspheres (Embospheres BioSphere Medical SA, Paris, France), polyvinyl alcohol particles (PVA, Ivalon, Cathmed Science; Paris, France) or/and steel coils (Cook, Denmark) after thoracic aortography and diagnostic selective and superselective catheterization of bronchial arteries and systemic collateral vessels in the bleeding lung area. Hemoptysis was due to bronchiectasis (55%), non-operable aspergillomas (15%), active tuberculosis (15%), malignancy (10%) and cystic fibrosis (5%). Mean duration of follow-up was 29+/-18 months. The recurrent-free time was calculated with Kaplan-Meier analysis. Immediate control of bleeding was achieved in all patients. Recurrent cases of hemoptysis were observed in 6/20 patients (30%) within 3 years and 4 of them (66.6%) occurred early in the first 3 months. Recurrent-free time was 9 months (standard error: 4) (95% confidence interval: 0-17). Repeated interventions were required in all early recurrences, due to either recanalization of the occluded arteries or non-bronchial systemic artery supply. Combined use of PVA and coils was proved effective in these cases. No serious complications were observed. BAE is an effective and safe intervention in cases of massive hemoptysis. However, recurrences are common and long-term follow-up is considered important with a view to perform repeated interventions with combination of embolic materials.
- 1 August 2008
- Vol. 27 (4) , 319-28
Percutaneous bronchial artery embolization in the management of massive hemoptysis in chronic lung diseases. Immediate and long-term outcomes.
Bronchial artery embolization (BAE) is a well-established, non-surgical procedure in the emergency treatment of massive hemoptysis. This study aims to evaluate the immediate and long-term prognosis of BAE for the management of massive hemoptysis in our center. Twenty consecutive patients (mean age: 59+/-14 years) with massive hemoptysis, underwent BAE with microspheres (Embospheres BioSphere Medical SA, Paris, France), polyvinyl alcohol particles (PVA, Ivalon, Cathmed Science; Paris, France) or/and steel coils (Cook, Denmark) after thoracic aortography and diagnostic selective and superselective catheterization of bronchial arteries and systemic collateral vessels in the bleeding lung area. Hemoptysis was due to bronchiectasis (55%), non-operable aspergillomas (15%), active tuberculosis (15%), malignancy (10%) and cystic fibrosis (5%). Mean duration of follow-up was 29+/-18 months. The recurrent-free time was calculated with Kaplan-Meier analysis. Immediate control of bleeding was achieved in all patients. Recurrent cases of hemoptysis were observed in 6/20 patients (30%) within 3 years and 4 of them (66.6%) occurred early in the first 3 months. Recurrent-free time was 9 months (standard error: 4) (95% confidence interval: 0-17). Repeated interventions were required in all early recurrences, due to either recanalization of the occluded arteries or non-bronchial systemic artery supply. Combined use of PVA and coils was proved effective in these cases. No serious complications were observed. BAE is an effective and safe intervention in cases of massive hemoptysis. However, recurrences are common and long-term follow-up is considered important with a view to perform repeated interventions with combination of embolic materials.
- Open Access
- 1 January 2008
- Published by Springer Nature in Thrombosis Journal
- Vol. 6 (1) , 9
Successful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series
Heparin-induced thrombocytopenia type II (HIT II) is a rare immune-mediated complication of heparin. The diagnosis of HIT is considered in patients exposed to heparin, presenting with thrombocytopenia and thrombosis.
- 1 January 2008
- Published by Springer Nature in Thrombosis Journal
- Vol. 6 (1) , 9
Open AccessSuccessful management of acute thromboembolic disease complicated with heparin induced thrombocytopenia type II (HIT II): a case series
Heparin-induced thrombocytopenia type II (HIT II) is a rare immune-mediated complication of heparin. The diagnosis of HIT is considered in patients exposed to heparin, presenting with thrombocytopenia and thrombosis.